ATTD Conference Brings Together Top Minds in Diabetes Research

in , , ,

Advanced Technologies & Treatments for Diabetes Conference April 27-30

Diabetes researchers from all over the world gather for the Advanced Technologies & Treatments for Diabetes (ATTD) Conference, which this year will take place in-person (as well as online) from April 27-30 in Barcelona, Spain.

Many of the latest advances will be discussed, including research that JDRF has funded to advance new breakthroughs and therapies for people with type 1 diabetes (T1D). In total, 32 researchers presenting are JDRF-funded, either now or in the past, including our own Sanjoy Dutta, Ph.D., JDRF’s Chief Scientific Officer, and Jeannette Soderberg, Ph.D., JDRF’s Director of European Research, who will chair a JDRF Session on the Utility of Patient-Reported Outcomes (PROs) in Therapy Development for T1D: Putting the End-User Upfront, which will feature renowned individuals from Tandem Diabetes Care, Novo Nordisk, Lexicon Pharmaceuticals, and ViaCyte.

Here are some more highlights of JDRF-funded research that will be featured at the conference:

  • Artificial Pancreas System Pivotal Trial: Results from the multi-center randomized insulin-only iLet bionic pancreas pivotal trial will be presented by Steven Russell, M.D., Ph.D., who received a JDRF grant from 2013-2016 to refine the iLet pancreas, based upon the work of Ed Damiano, Ph.D., CEO of Beta Bionics, who JDRF funded from 2009-2011, for his early research testing the safety and efficacy of a novel closed-loop system (including Firas El-Khatib, Ph.D., a JDRF postdoctoral fellow in his lab). The results of this work helped to inform the development of the iLet bionic pancreas.
    • Also in this Closed-Loop Updates Session are JDRF-funded:
      • Ohad Cohen, M.D., who will talk about real world data to optimize automated insulin delivery (AID) devices;
      • Boris Kovatchev, Ph.D., whose algorithm led to the Tandem Control-IQ™ artificial pancreas technology, who will present on long-term, real-life use of closed loop control;
      • Roman Hovorka, Ph.D., who generated the CamAPS® FX artificial pancreas system, on the applicability of closed loop solutions to type 2; and
      • Revital Nimri, D.Med., and Moshe Phillip, M.D., two co-founders of the DreaMed Diabetes company, who will offer highlights from the international consensus meeting on AID technology.

Stay tuned on Twitter (@JDRF) for exciting news at the ATTD Conference.